Strengthening the Group’s Management Structure
First written in FY2020-Q2. 12 of 17 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2019: 1 of 6 companies on the "Worse" side.
3 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「3. Strengthening the group management structure The company will strengthen its governance structure to one appropriate for a company listed on the Tokyo Stock Exchange Prime Market, strengthen its sustainability initiatives, contribute to the realization of a sustainable society, and link these efforts to its own growth.」
Strengthening the group management structure has taken concrete shape as strengthening governance and sustainability in line with the Prime Market. - FY2025AdvancedAnnual report
「3. Strengthening the group management structure The company will strengthen its governance structure to one appropriate for a company listed on the Tokyo Stock Exchange Prime Market, strengthen its sustainability initiatives, contribute to the realization of a sustainable society, and link these efforts to its own growth.」
Advancing group management in line with the Prime Market has taken concrete shape as a key initiative under Medium-Term Management Plan 2027, combining stronger governance with enhanced sustainability initiatives. - FY2024-Q3RestatedAnnual report
「Under this medium-term management plan, the following were established as practical priorities, and initiatives are being undertaken to achieve them: “1. Pursuing a pharmaceutical distribution model aligned with structural changes in the market and market characteristics,” “2. Evolving the distribution and marketing model in line with advances in healthcare DX,” and “3. Advancing group management in line with the Prime Market.”」
Advancing group management in line with the Prime Market has been reaffirmed as a practical priority under the Fifth Medium-Term Management Plan. - FY2024-Q2RestatedAnnual report
「Under this medium-term management plan, the following were established as practical priorities: “1. Pursuing a pharmaceutical distribution model aligned with structural changes in the market and market characteristics,” “2. Evolving the distribution and marketing model in line with advances in healthcare DX,” and “3. Advancing group management in line with the Prime Market.”」
Advancing group management in line with the Prime Market has been reaffirmed as a practical priority under the Fifth Medium-Term Management Plan. - FY2024-Q1RestatedAnnual report
「Under this medium-term management plan, the following were established as practical priorities: “1. Pursuing a pharmaceutical distribution model aligned with structural changes in the market and market characteristics,” “2. Evolving the distribution and marketing model in line with advances in healthcare DX,” and “3. Advancing group management in line with the Prime Market.”」
Advancing group management in line with the Prime Market has been reaffirmed as a practical priority under the Fifth Medium-Term Management Plan. - FY2023AdvancedAnnual report
「Progress has been made on the new approach strategy for the hospital market, one of the initiatives under this medium-term management plan. We will continue to focus on strengthening our presence in the growing hospital market by using this new approach to deliver products, services and information that our group has not previously been able to provide.」
The company reports progress on its new approach strategy for the hospital market and has moved to the stage of using previously unavailable products, services and information. - FY2023-Q1RestatedAnnual report
「Set as a practical priority: “3. Advancing group management in line with the Prime Market”」
Advancing group management in line with the Prime Market continues as a practical priority under the Fifth Medium-Term Management Plan. - FY2022ReframedAnnual report
「3. Advancing group management in line with the Prime Market」
The wording has been changed from strengthening the existing group management structure to advancing group management in line with the Tokyo Stock Exchange’s Prime Market. - FY2022-Q3RestatedAnnual report
「The company established the following practical initiatives: “1. Establishing a prescription pharmaceutical wholesaling business structure that continues to generate profit even in a low-growth environment”; “2. Increasing revenue through the growth and expansion of emerging businesses (*)”; and “3. Strengthening the group management structure.”」
Strengthening the group management structure continues to be a stated priority in the final year of the Fourth Medium-Term Management Plan. - FY2022-Q2RestatedAnnual report
「The company established the following practical initiatives: “1. Establishing a prescription pharmaceutical wholesaling business structure that continues to generate profit even in a low-growth environment”; “2. Increasing revenue through the growth and expansion of emerging businesses (*)”; and “3. Strengthening the group management structure.”」
Strengthening the group management structure continues to be a stated priority in the final year of the Fourth Medium-Term Management Plan. - FY2022-Q1RestatedAnnual report
「The company established the following practical initiatives: “1. Establishing a prescription pharmaceutical wholesaling business structure that continues to generate profit even in a low-growth environment”; “2. Increasing revenue through the growth and expansion of emerging businesses (*)”; and “3. Strengthening the group management structure.”」
Strengthening the group management structure continues to be a stated priority in the final year of the Fourth Medium-Term Management Plan. - FY2021-Q3RestatedAnnual report
「The company established the following practical initiatives: “1. Establishing a prescription pharmaceutical wholesaling business structure that continues to generate profit even in a low-growth environment”; “2. Increasing revenue through the growth and expansion of emerging businesses (*)”; and “3. Strengthening the group management structure.”」
Strengthening the group management structure continues as a practical priority under the Fourth Medium-Term Management Plan. - FY2021-Q2RestatedAnnual report
「The company established “3. Strengthening the group management structure.”」
Strengthening the group management structure continues as a practical priority under the Fourth Medium-Term Management Plan. - FY2021-Q1RestatedAnnual report
「The company established the following practical initiatives: “1. Establishing a prescription pharmaceutical wholesaling business structure that continues to generate profit even in a low-growth environment”; “2. Increasing revenue through the growth and expansion of emerging businesses (*)”; and “3. Strengthening the group management structure.”」
Strengthening the group management structure continues as a practical priority under the Fourth Medium-Term Management Plan. - FY2020RestatedAnnual report
「3. Strengthening the group management structure」
Strengthening the group management structure continues as a practical priority under the Fourth Medium-Term Management Plan. - FY2020-Q3RestatedAnnual report
「The company established the following practical initiatives: “1. Establishing a prescription pharmaceutical wholesaling business structure that continues to generate profit even in a low-growth environment”; “2. Increasing revenue through the growth and expansion of emerging businesses (*1)”; and “3. Strengthening the group management structure.”」
Strengthening the group management structure continues as a practical priority under the Fourth Medium-Term Management Plan. - FY2020-Q2First statedAnnual report
「The company established the following practical initiatives: “1. Establishing a prescription pharmaceutical wholesaling business structure that continues to generate profit even in a low-growth environment”; “2. Increasing revenue through the growth and expansion of emerging businesses (*1)”; and “3. Strengthening the group management structure.”」
The strengthening of the group management structure is explicitly identified as one of the new practical priorities under the Fourth Medium-Term Management Plan.